Drug intelligence / Profile preview

thallium (201tl) chloride

Development stage: Approved
Lead developer: Lantheus
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Thallium (201Tl) chloride (also known as thallous chloride Tl 201) is a diagnostic radiopharmaceutical used in nuclear medicine for myocardial perfusion imaging (MPI) to diagnose coronary artery disease, evaluate myocardial viability, and localize myocardial infarction. It is also utilized for the localization of parathyroid hyperactivity (such as parathyroid adenomas) and in tumor imaging. As a potassium analog, thallium-201 is actively transported into viable myocardial cells via the sodium/potassium-transporting ATPase (Na+/K+-ATPase) pump, with its intracellular accumulation being proportional to regional blood flow and cell viability. Areas of ischemia or infarction exhibit reduced uptake, which can be visualized using single-photon emission computed tomography (SPECT) or planar scintigraphy. Originally developed at Brookhaven National Laboratory and first commercialized by New England Nuclear (later DuPont, Bristol Myers Squibb, and Lantheus), thallium (201Tl) chloride is currently manufactured and supplied by companies such as Curium and PDRadiopharma.

Brand names: Thallous Chloride Tl 201
Other names: thallium (201Tl) chloridethallium chloridethallium chloride (201Tl) injectionthallium monochloridethallium-201 chloridethallium201 chloridethallium 201 chloridethallium-201 monochloridethallium201 monochloridethallium 201 monochloridethallous chloridethallous chloride (201Tl)thallous chloride Tl 201 injectionthallous chloride Tl-201

Targets

ATP1A (Sodium/potassium-transporting ATPase)

Beyond the preview

Go deeper on thallium (201tl) chloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on thallium (201tl) chloride.